Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues1

The HER-2/neu (HER-2) oncogene is expressed in normal epithelial surfaces at low levels and overexpressed in several types of tumors. The low immunogenicity against this self tumor Ag can be improved by developing epitopes with amino acid replacements in their sequences. In this study, three HER-2/neu.369 (HER-2.369) analogue peptides, produced by modifying both anchor positions by introducing L, V, or T at position 2 and V at the C terminus, were analyzed for their capacity to induce CTLs in vitro from human PBMC and in vivo in HLA-A2.1/Kb transgenic mice. One of the analogues (HER-2.369 V2V9) sensitized target cells for HER-2-specific recognition by human CTLs and induced specific CTLs in vitro at 100-fold lower concentrations than the HER-2.369 wild-type epitope. These CTLs were also able to recognize the wild-type epitope and HER-2-expressing tumors in an MHC-restricted manner. Furthermore, a 100-fold lower amount of the HER-2.369 V2V9 analogue compared with the wild-type epitope was required to induce CTLs in HLA-A2.1/Kb transgenic mice. However, the V2V9 analogue demonstrated only marginally better binding to the MHC class I A2 allele compared with wild type. To establish thermodynamic parameters, we developed radiolabeled F3*Y analogues from both the HER-2.369 epitope and the V2V9 analogue. Our results indicate that the high biological activity of the HER-2.369 V2V9 epitope is associated with a slower dissociation kinetic profile, resulting in an epitope with greater HLA-A2 stability.

[1]  P. Musiani,et al.  LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.

[2]  H. Fujii,et al.  Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Murray,et al.  Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex1 , 2002, The Journal of Immunology.

[4]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[5]  M. Ziol,et al.  Amino acid modifications in the wild type sequence p53 232–240 overcome the poor immunogenicity of this self tumour epitope , 2002, Journal of peptide science : an official publication of the European Peptide Society.

[6]  M. Cheever,et al.  Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[8]  A Choudhury,et al.  Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.

[9]  J. Schlom,et al.  Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  T. Eberlein,et al.  Modification of the HER2/NEU‐derived tumor antigen GP2 improves induction of GP2‐reactive cytotoxic T lymphocytes , 2001, International journal of cancer.

[11]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[12]  Alessandro Sette,et al.  Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.

[13]  F. Fallarino,et al.  Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[15]  Steven A. Rosenberg,et al.  Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.

[16]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[17]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[18]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[19]  Sylvia Janetzki,et al.  Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide , 2000, International journal of cancer.

[20]  J. Schlom,et al.  Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide , 2000, International journal of cancer.

[21]  P. Romero,et al.  Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue , 2000, The Journal of Immunology.

[22]  Shuqin Yan,et al.  Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is due to a Lack of Interactions with the Center of the Peptide* , 1999, The Journal of Biological Chemistry.

[23]  A Sette,et al.  Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.

[24]  Parkhurst,et al.  Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. , 1999, Journal of immunology.

[25]  G. Parmiani,et al.  A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. , 1999, Cancer research.

[26]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[27]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[28]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[29]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[30]  J. Sidney,et al.  The HLA-A0207 Peptide Binding Repertoire is Limited to a Subset of the A0201 Repertoire , 1997 .

[31]  J. Sidney,et al.  Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.

[32]  J. Sidney,et al.  The HLA-A*0207 peptide binding repertoire is limited to a subset of the A*0201 repertoire. , 1997, Human immunology.

[33]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[34]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[35]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[36]  J. Wharton,et al.  Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. , 1994, Cellular immunology.

[37]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[38]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[40]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[41]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.